本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、董事会会议召开情况 长江医药控股股份有限公司（以下简称"公司"）第五届董事会第二十五次 会议于2025年5月6日以现场加通讯表决方式召开。因情况紧急，会议通知于2025 年5月6日以电子邮件方式送达，会议召集人王波先生在会议上进行了说明。本次 会议由王波先生主持，应参与表决董事9人，实际参与表决董事9人，其中杜士明 先生、孙照宏先生、杨长生先生、顾紫光先生、韩庆凯先生以通讯方式出席并表 决。本次会议召集、召开的程序、方式符合有关法律、行政法规、部门规章、规 范性文件和公司章程规定。 二、董事会会议审议情况 证券代码：300391 证券简称：长药控股 公告编号：2025-054 长江医药控股股份有限公司 第五届董事会第二十五次会议决议公告 1、关于签署重整投资协议暨关联交易的议案。 表决情况：赞成：7票；反对：0票；弃权：0票；关联董事翁浩、赵守军回避 表决。 本议案已经公司独立董事第四次专门会议审议通过。 详情参见与本公告同日披露于巨潮资讯网的《关于签署重整投资协议暨关联 交易的公告》。 表决结果：通过。 2 ...

一、证监会联合交易所公布了五一休市安排，A股要"放假"了，2025年5月1日（周四）到5月5日（周一）一共休市5天，5月6日（周二）恢复正常交易。 不过，又有两家上市公司"割韭菜"了，四月财报季真是雷声滚滚，一不小心踩到就损失惨重。长药控股和宏达新材估计明天又要跌停了。这两个公司之前还 风光过，后来一看营收不到3亿，直接被剔除出列表。小盘股玩的就是波段，量化交易更喜欢，但风险也更大。 三、三大指数窄幅震荡，PEEK材料、美容护理板块涨幅居前。 个股弱修复为主，微盘股开始反弹修复，存量资金开始逐步发掘财报披露后行情有企稳迹象的个股。策略上，五月业绩真空期，明天应该会有资金拿先手。 具体来看，资金的方向还是AI＋人工智能方向，人形机器人方向，算力方向等，跌的多的反弹也会多一些，涨的多的横盘几天，市场要修复的话板块的节 奏是同步的。 四、三大指数低开高走，全天窄幅震荡，沪指缩量震荡微跌0.05%。 二、4月底是上市公司披露年报的最后截止时间。 业绩好的公司早就把财报亮出来了，那些业绩差的、暴雷的公司，总是拖到最后一刻才公布真相。 明天是节前最后一天，也是业绩利空出清的日子，说不定指数会放量大涨。要是真大涨了，可以关 ...

证券代码：300391 证券简称：长药控股 公告编号：2025-053 长江医药控股股份有限公司 重大诉讼的进展公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 重要内容提示： 原告武汉农村商业银行股份有限公司武昌支行与被告湖北长江星医药股份 有限公司、湖北长江丰医药有限公司、湖北长江源制药有限公司、石首市国际大 酒店有限公司、湖北长江大药房连锁有限公司、湖北舒惠涛药业有限公司、湖北 长江大药房连锁武汉有限公司、长江医药控股股份有限公司、罗明、张莉、田良 辉金融借款合同纠纷案目前处于强制执行阶段。2025年4月25日，湖北省武汉市 中级人民法院裁定冻结被执行人湖北长江大药房连锁有限公司、田良辉持有的湖 北长江星医药股份有限公司的股权。本案的涉案金额198,542,153.06元，预计不 会对公司当期损益产生影响。 一、诉讼事项受理的基本情况 2025年4月27日，长江医药控股股份有限公司（以下简称"公司"、"长药 控股"）收到湖北省武汉市中级人民法院执行裁定书。湖北省武汉市中级人民法 院所在地为湖北省武汉市江汉区常青路156号。诉讼各方当事人如下： 申请执行 ...

证券代码：300391 证券简称：长药控股 公告编号：2025-052 长江医药控股股份有限公司 关于2025年第一季度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 长江医药控股股份有限公司（以下简称"公司"或"本公司"）于 2025 年 4 月 25 日召开的第五届董事会第二十四次会议、第五届监事会第十二次会议会 议审议通过了《关于 2025 年第一季度计提资产减值准备的议案》。依据《深圳 证券交易所创业板股票上市规则》等法律法规相关规定，具体如下： 一、本次计提信用减值准备、资产减值准备情况 （一）本次计提信用减值准备、资产减值准备情况概述 1、本次计提信用减值准备、资产减值准备的原因 公司本次计提信用减值准备、资产减值准备，是依照《企业会计准则》及公 司会计政策的相关规定进行的。公司对截至 2025 年 3 月 31 日各类资产进行了全 面清查，并对各类资产进行了充分的评估和分析，本着谨慎性原则，公司需对可 能发生减值损失的相关资产进行计提减值准备。 2、本次计提信用减值准备、资产减值准备的资产范围和总金额 本次计提的资产减值准备 ...

长江医药控股股份有限公司 第五届监事会第十二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、监事会会议召开情况 证券代码：300391 证券简称：长药控股 公告编号：2025-050 1、2025年第一季度报告 经审核，监事会认为董事会编制和审议公司2025年第一季度报告的程序符合法 律、行政法规及中国证监会的规定，报告内容真实、准确、完整地反映了公司的实 际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 详情参见与本公告同日披露于巨潮资讯网的《2025年第一季度报告》。 表决情况：赞成：3票；反对：0票；弃权：0票。 表决结果：通过。 2、关于2025年第一季度计提资产减值准备的议案 监事会认为：公司本次计提资产减值准备的决议程序合法，依据充分，符合《企 业会计准则》等相关规定，符合公司实际情况，计提后能更公允地反映公司资产状 况，同意本次计提资产减值准备。 详情参见与本公告同日披露于巨潮资讯网的《关于2025年第一季度计提资产减 值准备的公告》。 长江医药控股股份有限公司（以下简称"公司"）第五届监事会第十二次会 议于2025年4月 ...

证券代码：300391 证券简称：长药控股 公告编号：2025-049 长江医药控股股份有限公司 第五届董事会第二十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、董事会会议召开情况 长江医药控股股份有限公司（以下简称"公司"）第五届董事会第二十四次 会议于2025年4月25日以现场加通讯表决方式在公司会议室召开，会议通知已于 2025年4月15日以电子邮件方式送达。本次会议由王波先生主持，应参与表决董事 9人，实际参与表决董事9人，其中顾紫光先生、韩庆凯先生以通讯方式出席并表 决。本次会议为董事会定期会议，召集、召开的程序、方式符合有关法律、行政 法规、部门规章、规范性文件和公司章程规定。 2、关于 2025 年第一季度计提资产减值准备的议案 本议案已经公司董事会审计委员会审议通过。 详情参见与本公告同日披露于巨潮资讯网的《关于 2025 年第一季度计提资产 减值准备的公告》。 二、董事会会议审议情况 1、2025 年第一季度报告 本议案的财务报告部分已经公司董事会审计委员会审议通过。 详情参见与本公告同日披露于巨潮资讯网的《2025 ...

Financial Performance - The company's revenue for Q1 2025 was ¥103,683,885.34, representing a 75.46% increase compared to ¥59,091,762.31 in the same period last year[5] - The net loss attributable to shareholders was ¥60,812,317.13, which is a 28.01% increase from a loss of ¥47,505,902.27 in the previous year[5] - The net cash flow from operating activities was -¥71,835,780.49, a decrease of 118.90% compared to -¥32,816,721.93 in the same period last year[5] - The company's basic earnings per share were -¥0.1736, down 28.02% from -¥0.1356 in the same period last year[5] - The weighted average return on equity improved to -13.13%, a 14.59% increase from -27.72% in the previous year[5] - The net profit for the current period was a loss of ¥89,396,554.98, compared to a loss of ¥81,120,269.42 in the previous period, indicating a deterioration in profitability[34] Revenue and Costs - The increase in revenue was primarily driven by the pharmaceutical segment, which saw a significant rise in income[9] - Total operating revenue for the current period reached ¥103,683,885.34, a significant increase from ¥59,091,762.31 in the previous period, representing a growth of approximately 75.4%[33] - Total operating costs increased to ¥164,016,116.81 from ¥89,749,307.79, marking a rise of about 83.0%[34] Shareholder Information - The company reported a total of 20,224 common shareholders at the end of the reporting period[11] - The top shareholder, Changxing Shengshi Fenghua Business Co., Ltd., holds 10.11% of the shares, amounting to 35,423,600 shares[11] Financial Distress and Liabilities - The company's net assets attributable to the parent company as of December 31, 2024, were -432,840,659.21 CNY, with retained earnings at -1,589,707,417.48 CNY, indicating significant financial distress[13] - The total liabilities of the company as of the latest report were 2.553 billion CNY, compared to 2.417 billion CNY in the previous period, reflecting an increase in financial obligations[31] - The company's total equity attributable to shareholders was -493,652,976.34 CNY, highlighting a critical equity deficiency[31] - The company faces significant risks of bankruptcy and delisting if it fails to meet the Shenzhen Stock Exchange's requirements in the upcoming fiscal year[17] Cash Flow and Investments - Cash and cash equivalents at the end of the period totaled ¥3,289,786.32, down from ¥6,301,111.84 at the beginning of the period[39] - The company reported an investment cash inflow of ¥1,320,000.00, while the cash outflow for investment activities was ¥145,439.20, resulting in a net cash flow from investing activities of ¥1,174,560.80[38] - Financing activities generated a net cash flow of ¥68,545,138.96, an increase from ¥31,502,907.79 in the previous period[38] - The company received other cash related to financing activities amounting to ¥71,555,872.71, compared to ¥49,443,197.38 in the previous period[38] Restructuring and Legal Issues - The company entered pre-restructuring on January 20, 2025, with uncertainty regarding its ability to proceed with formal restructuring[14] - The court has ruled for the bankruptcy restructuring of its subsidiary, indicating potential complications for the parent company's operations[14] - As of April 22, 2025, the company's stock was subject to delisting risk warning due to financial performance issues, including negative net profit and net assets[18] Asset Overview - The total assets at the end of the reporting period were ¥2,042,496,723.36, reflecting a 2.34% increase from ¥1,995,717,642.12 at the end of the previous year[5] - The company's total assets amounted to 2.042 billion CNY, showing a slight increase from 1.996 billion CNY previously[31] Product Development - The company did not report any significant new product developments or market expansions during this period[40]

Investment Rating - The report indicates a positive outlook for the weight loss drug sector within the pharmaceutical and biotechnology industry, suggesting potential acceleration in business development (BD) opportunities [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a slight decline of -0.36% from April 14 to April 18, underperforming compared to the Wind All A index (0.39%) and the CSI 300 index (0.59). The market showed a preference for defensive sectors, with chemical preparations (0.62%), traditional Chinese medicine (0.6%), and offline pharmacies (0.19%) showing minor gains, while blood products (-4.39%), other biological products (-1.78%), and vaccines (-1.49%) saw significant pullbacks [2][7]. - The GLP-1 receptor agonists are expected to catalyze growth in the weight loss drug sector. Notably, Eli Lilly announced positive results from the Phase III ACHIEVE-1 study for its oral drug Orforglipron, which is set to expand the application of GLP-1 drugs. This class of drugs is becoming a focal point for multinational corporations (MNCs) in the metabolic disease space, with domestic companies poised to benefit from rapid innovation and lower R&D costs [2][12]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance from April 14 to April 18 showed a decline of -0.36%, with the market favoring defensive stocks. The top gainers included Shuangcheng Pharmaceutical (56.4%), Kangpeng Technology (56.3%), and Lifang Pharmaceutical (47.1%), while the largest losers were *ST Jiyuan (-50.7%), Hasanlian (-19.1%), and Changyao Holdings (-18.5%) [7][10]. Industry News and Key Company Announcements - On April 17, Eli Lilly announced that its oral GLP-1 receptor agonist Orforglipron achieved positive results in its Phase III study, showing significant reductions in A1C levels and weight loss compared to placebo [12]. - Pfizer terminated the development of its GLP-1 small molecule receptor agonist Danuglipron due to potential liver damage in trial participants [12]. - The report highlights several companies making strides in the industry, including the approval of new indications for Merck's Gardasil 9 HPV vaccine and the progress of various clinical trials for innovative drugs [13][14].

Market Performance - The A-share market saw mixed performance in the past week, with the Shanghai Composite Index closing at 3276.73 points, up 1.19% for the week, while the Shenzhen Component Index fell 0.54% to 9781.65 points, and the ChiNext Index decreased 0.64% to 1913.97 points [2] - Approximately 42% of stocks experienced gains during the week, with 113 stocks rising over 15% and 32 stocks declining more than 15% [2] Sector Performance - The leading sectors for gains included internet e-commerce, food processing, real estate, banking, and textile manufacturing, while sectors that saw declines included agriculture, aquaculture, military electronics, shipping, and photovoltaic equipment [2] Government Initiatives - The State Council meeting on April 18 emphasized the need to stabilize the stock market and promote the healthy development of the real estate market, alongside measures to support employment and domestic demand [4] - The meeting highlighted the importance of targeted support for foreign investment and the need for effective implementation of policies to ensure they reach businesses and the public [4] Trade and Economic Policies - The U.S. government is considering forming a task force to address the supply chain crisis caused by high tariffs on Chinese goods, indicating a potential shift in trade policy [5] - The Ministry of Commerce announced plans to expand reform tasks for free trade zones in Guangdong, Tianjin, and Fujian, aiming to enhance their role in national strategies and respond to external risks [6][7] Technology and Innovation - Hainan University announced breakthroughs in brain-computer interface technology, achieving full-chain autonomy in chip development, which is expected to enhance China's capabilities in this field [8] - The cross-border e-commerce platform Dunhuang.com has seen a significant increase in user engagement, with over 278,000 registered suppliers and a surge in new buyer registrations [8][9] Investment Opportunities - The human-shaped robot market is anticipated to grow, with the upcoming launch of the "Tian Gong 2.0" robot expected to be priced similarly to entry-level cars, indicating a potential investment opportunity in the robotics sector [10] - The surge in demand for high-cost performance products among U.S. consumers is expected to drive continued growth in cross-border e-commerce platforms [9]

Important Market News - The 2025 China Internet Entrepreneurs Forum was held in Beijing on April 20, emphasizing the need for breakthroughs in original, frontier, and disruptive technologies within the internet industry to support modernization and digital transformation [1] Industry Insights - On April 19, the world's first humanoid robot half-marathon champion was born in Beijing, with the humanoid robot TianGong Ultra completing the race in 2 hours, 40 minutes, and 42 seconds. The Beijing Humanoid Robot Innovation Center, initiated by UBTECH, aims to accelerate the development of general-purpose robots, with the humanoid robot market expected to exceed 1 trillion yuan by 2026 [2] - In a press conference regarding Q1 economic data, it was reported that nearly 70% of key products in the equipment industry saw production growth of 69.2%, an increase of 16.7 percentage points year-on-year. The Ministry of Industry and Information Technology plans to introduce new growth stabilization plans for key industries [3] - Huawei is set to hold a strategic and product launch event on April 22, where it will unveil a megawatt-level ultra-fast charging product capable of delivering 20 kWh in one minute, significantly enhancing electric vehicle charging efficiency. The global megawatt charging market is projected to grow from approximately $6.406 million in 2024 to $1.5 billion by 2030, with a compound annual growth rate of 80.91% [4] - The National Development and Reform Commission is promoting the development of the low-altitude economy, with a focus on safety and health. The low-altitude economy is expected to become a new growth engine for urban economies, with a market size projected to reach trillions as policies and infrastructure accelerate [6] Risk Alerts - Shenghe Resources announced a new exclusive distribution agreement with MP Company for rare earth products, with no significant impact on operations despite a temporary halt in exports due to tariffs [7] - Hongda New Materials reported that its 2024 financial statements may include a significant uncertainty paragraph regarding its ability to continue as a going concern, which could lead to risk warnings for its stock [8] - ST Tianlong announced that due to negative net assets, its stock will be subject to delisting risk warnings, with a change in stock name to "*ST Tianlong" [9]